GlobeNewswire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
📊
AI Sentiment
Positive
6/10
- Home
- MDGL
as of 02-10-2026 3:43pm EST
$476.87
$11.39
-2.33%
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WEST CONSHOHOCKEN |
| Market Cap: | 12.5B | IPO Year: | N/A |
| Target Price: | $631.46 | AVG Volume (30 days): | 302.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -13.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $265.00 - $615.00 | Next Earning Date: | 02-19-2026 |
| Revenue: | $740,640,000 | Revenue Growth: | 864.21% |
| Revenue Growth (this year): | 435.42% | Revenue Growth (next year): | 54.39% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -161631000.0 | FCF Growth: | N/A |
AI-Powered MDGL Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 78.48%
78.48%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Madrigal Pharmaceuticals Inc. (MDGL)
Taub Rebecca
Sell
Director
MDGL Jan 26, 2026
Avg Cost/Share
$492.42
Shares
647
Total Value
$318,595.74
Owned After
452,704
SEC Form 4
Huntsman Carole
Sell
Chief Commercial Officer
MDGL Jan 26, 2026
Avg Cost/Share
$493.51
Shares
910
Total Value
$449,339.10
Owned After
9,122
Sibold William John
Sell
President and CEO
MDGL Jan 26, 2026
Avg Cost/Share
$492.42
Shares
1,577
Total Value
$776,546.34
Owned After
148,497
SEC Form 4
Taub Rebecca
Sell
Director
MDGL Jan 20, 2026
Avg Cost/Share
$490.77
Shares
2,238
Total Value
$1,098,343.26
Owned After
452,704
SEC Form 4
Kelley Shannon T
Sell
General Counsel
MDGL Jan 20, 2026
Avg Cost/Share
$496.09
Shares
692
Total Value
$344,173.11
Owned After
8,481
Taub Rebecca
Sell
Director
MDGL Jan 9, 2026
Avg Cost/Share
$528.25
Shares
18,650
Total Value
$9,749,392.08
Owned After
452,704
FRIEDMAN PAUL A
Sell
Director
MDGL Jan 9, 2026
Avg Cost/Share
$527.73
Shares
24,800
Total Value
$12,963,304.52
Owned After
187,164
Sibold William John
Sell
President and CEO
MDGL Dec 4, 2025
Avg Cost/Share
$575.34
Shares
2,400
Total Value
$1,380,816.00
Owned After
148,497
SEC Form 4
Dier Mardi
Sell
EVP and CFO
MDGL Dec 2, 2025
Avg Cost/Share
$581.45
Shares
4,173
Total Value
$2,413,416.41
Owned After
10,520
Levy Richard S
Sell
Director
MDGL Nov 13, 2025
Avg Cost/Share
$522.34
Shares
8,500
Total Value
$4,428,197.57
Owned After
29,551
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Taub Rebecca | MDGL | Director | Jan 26, 2026 | Sell | $492.42 | 647 | $318,595.74 | 452,704 | |
| Huntsman Carole | MDGL | Chief Commercial Officer | Jan 26, 2026 | Sell | $493.51 | 910 | $449,339.10 | 9,122 | |
| Sibold William John | MDGL | President and CEO | Jan 26, 2026 | Sell | $492.42 | 1,577 | $776,546.34 | 148,497 | |
| Taub Rebecca | MDGL | Director | Jan 20, 2026 | Sell | $490.77 | 2,238 | $1,098,343.26 | 452,704 | |
| Kelley Shannon T | MDGL | General Counsel | Jan 20, 2026 | Sell | $496.09 | 692 | $344,173.11 | 8,481 | |
| Taub Rebecca | MDGL | Director | Jan 9, 2026 | Sell | $528.25 | 18,650 | $9,749,392.08 | 452,704 | |
| FRIEDMAN PAUL A | MDGL | Director | Jan 9, 2026 | Sell | $527.73 | 24,800 | $12,963,304.52 | 187,164 | |
| Sibold William John | MDGL | President and CEO | Dec 4, 2025 | Sell | $575.34 | 2,400 | $1,380,816.00 | 148,497 | |
| Dier Mardi | MDGL | EVP and CFO | Dec 2, 2025 | Sell | $581.45 | 4,173 | $2,413,416.41 | 10,520 | |
| Levy Richard S | MDGL | Director | Nov 13, 2025 | Sell | $522.34 | 8,500 | $4,428,197.57 | 29,551 |
Latest Madrigal Pharmaceuticals Inc. News
MDGL Breaking Stock News: Dive into MDGL Ticker-Specific Updates for Smart Investing
Compare MDGL vs Leading Stocks
See how MDGL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MDGL Madrigal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.